Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
IBI-20089 and Lucentis for Neovascular AMD
NCT01175395Phase 2Completed
- Sponsor
- University of Illinois Chicago
- Start
- Sep 2010
- Primary completion
- Jan 2013
- Modality
- Small Molecules, Drug Delivery Systems
- Countries
- 1
01
Overview
Phase 2, open-label trial of IBI-20089 in exudative macular degeneration and choroidal neovascularization (CNV), sponsored by University of Illinois Chicago. Primary endpoint: Safety and Tolerability of IBI-20089 at 360 days. Started Sep 2010; status: completed.
02
Drugs
IBI-20089
03
Conditions
exudative macular degenerationchoroidal neovascularization (CNV)
Beyond the preview
Go deeper on NCT01175395.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT01175395.